公开(公告)号：US20240199550A1

公开(公告)日：2024-06-20

申请号：US18416741

申请日：2024-01-18

申请人： Amgen Inc. ,  Cytokinetics, Inc.

发明人： Henry MORRISON ,  Sheng CUI ,  Kyle QUASDORF ,  Evelyn YANEZ ,  Bin Peter QUAN ,  Ron C. KELLY ,  Sebastien CAILLE ,  Lingyun XIAO ,  David PEARSON ,  Jaclyn RAEBURN ,  Alisa GOLIGHTLY ,  Bradley MORGAN ,  Matthew PETERSON ,  Alex EBERLIN ,  Alexander OBLEZOV

IPC分类号： C07D213/75

CPC分类号： C07D213/75 ,  C07B2200/13

摘要： Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

公开(公告)号：US20220153700A1

公开(公告)日：2022-05-19

申请号：US17448833

申请日：2021-09-24

申请人： Cytokinetics, Inc.

发明人： Sheng CUI ,  Henry MORRISON ,  Karthik NAGAPUDI ,  Shawn D. WALKER ,  Charles BERNARD ,  Karl Bennett HANSEN ,  Neil Fred LANGILLE ,  Alan Martin ALLGEIER ,  Steven M. MENNEN ,  Jacqueline C.S WOO ,  Bradley Paul MORGAN ,  Alex MUCI

IPC分类号： C07D213/75 ,  A61K9/20 ,  A61K31/496 ,  A61K47/38

摘要： Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

公开(公告)号：US20240101517A1

公开(公告)日：2024-03-28

申请号：US18520156

申请日：2023-11-27

申请人： Cytokinetics, Inc.

发明人： Sheng CUI ,  Henry MORRISON ,  Karthik NAGAPUDI ,  Shawn D. WALKER ,  Charles BERNARD ,  Karl Bennett HANSEN ,  Neil Fred LANGILLE ,  Alan Martin ALLGEIER ,  Steven MENNEN ,  Jacqueline C.S. WOO ,  Bradley Paul MORGAN ,  Alex MUCI (DECEASED)

IPC分类号： C07D213/75 ,  A61K9/20 ,  A61K31/496 ,  A61K47/38

CPC分类号： C07D213/75 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/496 ,  A61K47/38

摘要： Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

公开(公告)号：US20230044617A1

公开(公告)日：2023-02-09

申请号：US17930695

申请日：2022-09-08

申请人： Cytokinetics, Inc.

发明人： Sheng CUI ,  Henry MORRISON ,  Karthik NAGAPUDI ,  Shawn D. WALKER ,  Charles BERNARD ,  Karl Bennett HANSEN ,  Neil Fred LANGILLE ,  Alan Martin ALLGEIER ,  Steven MENNEN ,  Jacqueline C.S. WOO ,  Bradley Paul MORGAN ,  Alex MUCI

IPC分类号： C07D213/75 ,  A61K9/20 ,  A61K31/496 ,  A61K47/38

摘要： Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

公开(公告)号：US20240317687A1

公开(公告)日：2024-09-26

申请号：US18421849

申请日：2024-01-24

申请人： Cytokinetics, Inc.

发明人： Sheng CUI ,  Henry MORRISON ,  Karthik NAGAPUDI ,  Shawn D. WALKER ,  Charles BERNARD ,  Karl Bennett HANSEN ,  Neil Fred LANGILLE ,  Alan Martin ALLGEIER ,  Steven M. MENNEN ,  Jacqueline C.S. WOO ,  Bradley Paul MORGAN ,  Alex MUCI (Deceased)

IPC分类号： C07D213/75 ,  A61K9/20 ,  A61K31/496 ,  A61K47/38

CPC分类号： C07D213/75 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/496 ,  A61K47/38

摘要： Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

公开(公告)号：US20230167130A1

公开(公告)日：2023-06-01

申请号：US17922619

申请日：2021-05-05

申请人： AMGEN INC.

发明人： Austin G. SMITH ,  Jason S. TEDROW ,  Gabrielle ST-PIERRE ,  Oliver Ralf THIEL ,  Liang HUANG ,  Philipp C. ROOSEN ,  John T. COLYER ,  Kyle D. BAUCOM ,  Ari ERICSON ,  Matthew G. BEAVER ,  Rahul P. SANGODKAR ,  Michael A. LOVETTE ,  Robert Ronald MILBURN ,  Alan H. CHERNEY ,  Sheng CUI

IPC分类号： C07D513/10 ,  C07D267/16

CPC分类号： C07D513/10 ,  C07D267/16

摘要： Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound F that can be used to prepare them where the variable PG is as defined herein. In particular, provided herein are processes for synthesizing compound A1, and salts or solvates thereof and compound A2, and salts and solvates thereof.

公开(公告)号：US20170190739A1

公开(公告)日：2017-07-06

申请号：US15300209

申请日：2015-04-03

申请人： AMGEN INC.

发明人： Jeroen BEZEMER ,  Ying CHEN ,  Richard CROCKETT ,  Kevin CROSSLEY ,  Sheng CUI ,  Liang HUANG ,  Sian JONES ,  Asher LOWER ,  Krishnakumar RANGANATHAN

IPC分类号： C07K7/06 ,  C07K1/107

CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K1/1075

摘要： A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided. AMG 416 is a synthetic, eight amino-acid selective peptide agonist of the calcium sensing receptor. It is being developed as an intravenous treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney disease—mineral and bone disorder (CKD-MBD).

公开(公告)号：US20130345432A1

公开(公告)日：2013-12-26

申请号：US13955343

申请日：2013-07-31

申请人： Amgen Inc.

发明人： Seb CAILLE ,  Sheng CUI ,  Xiang WANG ,  Margaret FAUL

IPC分类号： C07D277/54

CPC分类号： C07D277/54

摘要： The invention provides two process for synthesizing substituted aminothiazolone compounds as inhibitors of 11-β-hydroxy steroid dehydrogenase type 1. The processes allow the stereoselective synthesis of the desired compounds without the use of stoichiometric amounts of chiral catalysts.

摘要翻译： 本发明提供两种合成取代的氨基噻唑酮化合物作为11型11-β-羟基类固醇脱氢酶抑制剂的方法。该方法允许所需化合物的立体选择性合成而不使用化学计量的手性催化剂。

公开(公告)号：US20210284617A1

公开(公告)日：2021-09-16

申请号：US16327079

申请日：2017-08-03

申请人： Amgen Inc.

发明人： Matthew BEAVER ,  Sheng CUI ,  Xiangqing SHI

IPC分类号： C07D301/12 ,  B01J31/16

摘要： The present invention provides new methods for preparing compound 5, and pharmaceutically acceptable salts thereof, of structure Compound 5, or a pharmaceutically acceptable salt thereof, is an important intermediate in the synthesis of carfilzomib. The invention further provides methods of making a useful manganese catalyst that may be used in the epoxidation step of the present invention.

公开(公告)号：US20230183164A1

公开(公告)日：2023-06-15

申请号：US17920084

申请日：2021-05-04

申请人： AMGEN INC.

发明人： Austin G. SMITH ,  Michael T. CORBETT ,  Neil Fred LANGILLE ,  Kyle D. BAUCOM ,  Peter K. DORNAN ,  Gabrielle ST- PIERRE ,  Philipp C. ROOSEN ,  Sheng CUI ,  Roberto PROFETA

IPC分类号： C07C67/62 ,  C07D249/18 ,  C07D519/00 ,  C07D513/08

CPC分类号： C07C67/62 ,  C07D249/18 ,  C07D519/00 ,  C07D513/08 ,  C07B2200/13

摘要： Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound F, or a salt thereof, wherein R1 and OPG2 are described herein. Compound F can be useful in synthesizing compound A1, or a salt of solvate thereof, and compound A2, or a salt of solvate thereof.